secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001601485-24-000107
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024
--------------------------------------------------------------------------------

- Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).
- Strong correlation observed between T cell response and reduced risk of progression or death.
- Event-driven interim analysis from randomized Phase 2 trial of ELI-002 7P expected in first half of 2025.
- ELI-002 was well-tolerated with no Grade 3/4 adverse events or dose-limiting toxicities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/0001601485-24-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/angn-20241212.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer